DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ:ALKS) today announced that data from Alkermes’ schizophrenia portfolio will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference to be held in Florence, Italy on April 2-6, 2016. In addition to positive data from a phase 2 study of ALKS 3831, the company’s investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia, the company will present the designs of ongoing clinical studies of ALKS 3831, including the phase 3 pivotal studies.
